MX362709B - Microesferas de buprenorfina de fuerte carga de medicamento y su método de fabricación. - Google Patents
Microesferas de buprenorfina de fuerte carga de medicamento y su método de fabricación.Info
- Publication number
- MX362709B MX362709B MX2015012232A MX2015012232A MX362709B MX 362709 B MX362709 B MX 362709B MX 2015012232 A MX2015012232 A MX 2015012232A MX 2015012232 A MX2015012232 A MX 2015012232A MX 362709 B MX362709 B MX 362709B
- Authority
- MX
- Mexico
- Prior art keywords
- dispersed phase
- drug load
- high drug
- producing
- same
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000004005 microsphere Substances 0.000 title abstract 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title 1
- 229960001736 buprenorphine Drugs 0.000 title 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 238000004945 emulsification Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una formulación de microesferas de liberación sostenida con una fuerte carga de medicamento puede estar formada por un proceso continuo de emulsión de agua en aceite mediante la combinación de una fase orgánica dispersa con una fase acuosa continua. La fase dispersa puede incluir un polímero de encapsulado, un disolvente primario, como por ejemplo diclorometano, una cantidad farmacéuticamente eficaz de un principio activo que tiene una solubilidad con relación a la fase dispersa, y un codisolvente, como por ejemplo alcohol bencílico, que es capaz de aumentar la solubilidad del principio activo con relación a la fase dispersa. La fase continua puede incluir una solución acuosa de alcohol de polivinilo y agua.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/837,181 US9393211B2 (en) | 2013-03-15 | 2013-03-15 | High drug load buprenorphine microspheres and method of producing same |
| PCT/US2014/027982 WO2014143839A1 (en) | 2013-03-15 | 2014-03-14 | High drug load buprenorphine microspheres and method of producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012232A MX2015012232A (es) | 2015-12-01 |
| MX362709B true MX362709B (es) | 2019-02-05 |
Family
ID=51528078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012232A MX362709B (es) | 2013-03-15 | 2014-03-14 | Microesferas de buprenorfina de fuerte carga de medicamento y su método de fabricación. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9393211B2 (es) |
| EP (1) | EP2968577B1 (es) |
| JP (1) | JP6678571B2 (es) |
| CN (1) | CN105377301B (es) |
| BR (1) | BR112015022985A2 (es) |
| CA (1) | CA2904432A1 (es) |
| ES (1) | ES2717942T3 (es) |
| MX (1) | MX362709B (es) |
| WO (1) | WO2014143839A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| NZ581862A (en) | 2007-05-25 | 2012-06-29 | Tolmar Therapeutics Inc | Injectable subcutaneous formulation comprising risperidone capable of forming a solid, microporous implant in a patient |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| EP3791861A1 (en) * | 2012-07-26 | 2021-03-17 | Camurus AB | Opioid formulations |
| US9636308B2 (en) * | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3141241A1 (en) * | 2015-09-08 | 2017-03-15 | Andreas Voigt | Sustained release low dose formulations and uses thereof |
| CN105596298B (zh) * | 2015-12-18 | 2018-08-14 | 山东大学 | 一种包载丁丙诺啡的peg-plga缓释微球及其制备方法 |
| EP3419596A1 (en) * | 2016-02-23 | 2019-01-02 | BioDelivery Sciences International, Inc. | Sustained release buprenorphine microspheres (srbm) and methods of use thereof |
| RS63894B1 (sr) | 2016-09-13 | 2023-02-28 | Alar Pharmaceuticals Inc | Formulacije buprenorfina sa produženim oslobađanjem |
| US11524965B2 (en) * | 2018-05-11 | 2022-12-13 | Alar Pharmaceuticals Inc. | Long-acting injectable formulations and crystalline forms of buprenorphine derivatives |
| WO2021173373A1 (en) * | 2020-02-26 | 2021-09-02 | Fordoz Pharma Corp. | Injectable controlled-release formulations of progestogen drugs |
| AU2022226584A1 (en) | 2021-02-24 | 2023-08-17 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
| CN114392384B (zh) * | 2021-12-24 | 2023-04-11 | 河南驼人医疗器械研究院有限公司 | 一种制备高载药量栓塞微球的方法及收集装置 |
| CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
| WO2024097696A1 (en) * | 2022-10-31 | 2024-05-10 | Oakwood Laboratories, Llc | Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| EP1555023A3 (en) * | 1999-08-27 | 2005-09-28 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
| WO2001015699A1 (en) * | 1999-08-27 | 2001-03-08 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
| US7041320B1 (en) | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| US20050048115A1 (en) | 2003-08-27 | 2005-03-03 | Murty Mangena | Buprenorphine microspheres |
| TWI362947B (en) | 2007-03-08 | 2012-05-01 | Univ Kaohsiung Medical | Controlled release pharmaceutical composition and manufacture method thereof |
| US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
| KR101113044B1 (ko) * | 2008-08-29 | 2012-02-27 | 동국제약 주식회사 | 용매교류증발법에 의한 서방출성 미립구의 제조방법 |
| US20100086597A1 (en) | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide with a low initial burst |
| WO2011087496A1 (en) | 2010-01-13 | 2011-07-21 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide without an initial time lag |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
-
2013
- 2013-03-15 US US13/837,181 patent/US9393211B2/en active Active
-
2014
- 2014-03-14 BR BR112015022985A patent/BR112015022985A2/pt not_active IP Right Cessation
- 2014-03-14 EP EP14764439.7A patent/EP2968577B1/en active Active
- 2014-03-14 WO PCT/US2014/027982 patent/WO2014143839A1/en active Application Filing
- 2014-03-14 ES ES14764439T patent/ES2717942T3/es active Active
- 2014-03-14 CA CA2904432A patent/CA2904432A1/en not_active Abandoned
- 2014-03-14 MX MX2015012232A patent/MX362709B/es active IP Right Grant
- 2014-03-14 CN CN201480021351.9A patent/CN105377301B/zh active Active
- 2014-03-14 JP JP2016502675A patent/JP6678571B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105377301B (zh) | 2020-06-05 |
| CN105377301A (zh) | 2016-03-02 |
| US20140271869A1 (en) | 2014-09-18 |
| JP2016513721A (ja) | 2016-05-16 |
| US9393211B2 (en) | 2016-07-19 |
| WO2014143839A1 (en) | 2014-09-18 |
| EP2968577B1 (en) | 2019-01-02 |
| JP6678571B2 (ja) | 2020-04-08 |
| BR112015022985A2 (pt) | 2017-08-22 |
| EP2968577A1 (en) | 2016-01-20 |
| EP2968577A4 (en) | 2016-11-23 |
| ES2717942T3 (es) | 2019-06-26 |
| CA2904432A1 (en) | 2014-09-18 |
| MX2015012232A (es) | 2015-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012232A (es) | Microesferas de buprenorfina de fuerte carga de medicamento y su metodo de fabricacion. | |
| UY35298A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| CL2017003067A1 (es) | Piridinas sustituidas y método de uso | |
| BR112015023658A2 (pt) | formulação de vitamina d de liberação modificada, estabilizada e método de administração desta | |
| AR095160A1 (es) | Formulaciones farmacéuticas a prueba de alteraciones | |
| BR112015015758B8 (pt) | Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida | |
| CR20160438A (es) | Dispersión sólida amorfa que comprende taxano, comprimido que comprende la misma, y método para su preparación | |
| AR089990A1 (es) | Dispositivo con nucleo y recubrimiento para la liberacion de farmacos | |
| PH12016500793A1 (en) | Turmeric extract containing soft pastilles | |
| CO6351710A2 (es) | Composicion topica para el tratamiento de queratosis actinica | |
| UY35301A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| PH12017502149A1 (en) | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester | |
| CR20150297A (es) | Producto de comicronización que comprende acetato de ulipristal | |
| PH12018550212A1 (en) | Rotigotine behenate and preparation method and use thereof | |
| AU2016204395A1 (en) | Microspheres including oxidized cellulose | |
| CL2014002896A1 (es) | Una formulacion farmaceutica en la forma de una tableta recubierta que consiste de a) un nucleo obtenido a partir de una co-mezcla de manitol, croscarmelosa de sodio y al menos un compuestos activo, y b) un recubrimiento el cual se aplica en la forma de una solucion acuosa o que contiene agua y alcohol, y donde la tableta se desintegra rapidamente en presencia de humedad; y su proceso de preparacion. | |
| BR112017006918A2 (pt) | formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares | |
| MX2015012231A (es) | Microesferas de liberacion sostenida y metodo para producir las mismas. | |
| WO2012029076A3 (en) | Stable pharmaceutical composition | |
| MX2015017198A (es) | Matriz. | |
| PH12014501853A1 (en) | Sustained release oral solid preparation | |
| AR093922A1 (es) | Composicion farmaceutica que contiene telmisartan | |
| MY181172A (en) | Composite preparation comprising active ingredient-containing film coating layer | |
| AR095130A1 (es) | Formulación en dispersión sólida de un compuesto antiviral | |
| ES2494620A1 (es) | Proceso integrado de obtención de alcoholes monoinsaturados, biodiesel y productos biodegradables a partir de aceite de Jojoba |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |